Holen Sie sich die Stockscreener-App
29.01
0.14%
0.04
Handel nachbörslich:
29.00
-0.01
-0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - Insider Monkey
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
Ultragenyx's Q2 earnings exceed expectations, price target lowered to $128 by Canaccord. - AInvest
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser
RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News
Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize
Ultragenyx Pharmaceutical Q2 2025 Earnings: Revenue Beats Expectations, Loss Narrows - AInvest
Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
‘Urgent need’ for treatment drives GTX-102 study enrollment - Angelman Syndrome News
Ultragenyx Pharmaceutical Inc. stock momentum explainedFree Proven Entry Plan With Low Risk Trade - Newser
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges - TipRanks
‘On track to become profitable’: Marin County rare disorder drug maker narrows loss in Q2 - The North Bay Business Journal
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating - TipRanks
Ultragenyx (RARE) Q2 Revenue Up 13% - Nasdaq
Ultragenyx Pharmaceutical Inc. SEC 10-Q Report - TradingView
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
Ultragenyx outlines $640M–$670M 2025 revenue target as clinical milestones advance - MSN
Ultragenyx: Q2 Earnings Snapshot - New Haven Register
Price action breakdown for Ultragenyx Pharmaceutical Inc.Long Term Equity Screener with Safety Metrics - Newser
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx Pharmaceuticals: A High-Stakes Play in Rare Disease Gene Therapy - AInvest
Ultragenyx's Q2 2025 Earnings Call: Dissecting Contradictions on Setrusumab Efficacy, FDA Interactions, and Resubmission Strategy - AInvest
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript: Financial Results and Business Update - AInvest
Ultragenyx Sets 2025 Revenue Target at $640M-$670M Amid Clinical Advancements - AInvest
Ultragenyx Reports Growth Amidst Strategic Advancements - TipRanks
Earnings call transcript: Ultragenyx Q2 2025 beats EPS forecast, stock rises - Investing.com
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Ultragenyx Reports Better-Than-Expected Q2 Loss and RevenueNews and Statistics - IndexBox
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ultragenyx August 2025 slides: Pipeline advances toward approvals as revenue grows By Investing.com - Investing.com South Africa
Ultragenyx Q2 revenue rises 13% - MarketScreener
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):